Sustained Effects of Glucagon-Like Peptide-1 (GLP-1) Agonists on Blood Pressure in Obesity and Type 2 Diabetes: A Longitudinal Case Study.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Sustained Effects of Glucagon-Like Peptide-1 (GLP-1) Agonists on Blood Pressure in Obesity and Type 2 Diabetes: A Longitudinal Case Study.
- Published In:
- Cureus, 17(7), e88893 (2025)
- Authors:
- Joseph, Jimmy
- Database ID:
- RPEP-11654
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11654APA
Joseph, Jimmy. (2025). Sustained Effects of Glucagon-Like Peptide-1 (GLP-1) Agonists on Blood Pressure in Obesity and Type 2 Diabetes: A Longitudinal Case Study.. Cureus, 17(7), e88893. https://doi.org/10.7759/cureus.88893
MLA
Joseph, Jimmy. "Sustained Effects of Glucagon-Like Peptide-1 (GLP-1) Agonists on Blood Pressure in Obesity and Type 2 Diabetes: A Longitudinal Case Study.." Cureus, 2025. https://doi.org/10.7759/cureus.88893
RethinkPeptides
RethinkPeptides Research Database. "Sustained Effects of Glucagon-Like Peptide-1 (GLP-1) Agonist..." RPEP-11654. Retrieved from https://rethinkpeptides.com/research/joseph-2025-sustained-effects-of-glucagonlike
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.